-+ 0.00%
-+ 0.00%
-+ 0.00%

Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026

PUBT·05/12/2026 20:09:39
Listen to the news
Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026
  • Nurix Therapeutics flagged updated efficacy and safety findings for BTK degrader bexobrutideg (NX-5948) from an ongoing Phase 1a/b study in chronic lymphocytic leukemia, accepted for an oral presentation at EHA2026.
  • Results have not yet been presented; disclosure is scheduled for June 14, 2026, in Stockholm during a relapsed or refractory CLL session.
  • Company positioned the update as covering performance and tolerability across treatment lines, supporting continued development in CLL.
  • Bexobrutideg remains in clinical testing, with a pivotal single-arm Phase 2 study in relapsed or refractory CLL running alongside broader Phase 1 enrollment in B-cell malignancies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121605PRIMZONEFULLFEED9718082) on May 12, 2026, and is solely responsible for the information contained therein.